Palisade Bio Inc (PALI NASDAQ) stock market data APIs
$1.124
0.03(2.7%)
as of November 13, 2026
Try our APIs with
free plan!
Palisade Bio Inc Financial Data Overview
Price chart is built with
Anychart
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Prev. Close
1.124
Open
1.156
High
1.1581
Low
1.0749
52 wk Range
1.08-2.86
Market Cap
201 M
P/E Ratio
1.2174
Shares Outstanding
179 M
Revenue
500 K
EPS
-0.07
Beta
1.616
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Palisade Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Palisade Bio Inc data using free add-ons & libraries
Get Palisade Bio Inc Fundamental Data
Palisade Bio Inc Fundamental data includes:
- Net Revenue: 500 K
- EBITDA: -48 124 752
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-10
- EPS/Forecast: -0.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Palisade Bio Inc News
New
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
Palisade Bio, Inc. PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve ...
Palisade Bio Q2 Net Loss Expands; Plans Phase 2 ASCENTRA-UC Trial Enrollment In H2 2026; Stock Down
(RTTNews) - Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company, reported financial results for the second quarter ended June 30, 2026, reflecting a wider net loss and provided a bus...
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Oppenheimer on Thursday initiated coverage of Palisade Bio Inc., saying the stock offers investors...
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026...
Get Palisade Bio Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.